A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

Summary

The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.

Timeline

Start

2009-10

Primary completion

2010-11

Completion

2010-11

Outcome

Met primary endpoint

registry analysis (superiority or other test); Tazarotene Foam vs Vehicle Foam; p <0.001; ANCOVA NCT01017146 ↗

registry analysis (superiority or other test); Tazarotene Foam vs Vehicle Foam; p <0.001; Percentage of participants 35.6 NCT01017146 ↗

registry analysis (superiority or other test); Tazarotene Foam vs Vehicle Foam; p <0.001; Percentage of participants 28.8 NCT01017146 ↗

Publications

• Background Feldman SR, Werner CP, Alio Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr;12(4):438-46.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tazarotene	Small molecule	0.1 %	Topical

Indications